volving adeno-associated viral gene delivery has been completed (Phase I, clinical trial no. NCT00151216), 30 and 2 subsequent related trials have been initiated, also using adeno-associated viral gene delivery direct ly to the CNS (clinical trial nos. NCT01414985 and NCT01161576). A Phase II study investigating Cystagon for INCL (clinical trial no. NCT00028262) is active but is not currently recruiting.
Recent advances in stem cell biology utilizing transplantation of allogeneic neural stem cells may provide new therapeutic strategies for neurological diseases. 11, [20] [21] [22] In vitro studies have shown that HuCNS-SCs secrete the enzymes deficient in both INCL and LINCL and that these enzymes can be internalized by diseased cells. 26 In vivo animal studies of orthotopically transplanted HuCNSSCs demonstrate engraftment, self-renewal, migration, and region-specific differentiation. 25, 28 In a mouse model of INCL, transplantation of HuCNS-SCs resulted in neuroprotection of host neurons, reduction of lipofuscin, and delay in locomotor dysfunction. 5, 26 In theory, transplanted HuCNS-SCs could replace deficient soluble enzymes and offer the potential for cell-based cross-correction within the CNS (Fig. 1) .
We report the first-in-human clinical trial of direct CNS transplantation of prospectively isolated and highly purified allogeneic neural stem cells from a single cell bank to evaluate safety, tolerability, and preliminary clinical activity in patients with INCL and LINCL. As this study was the initial step in determining the therapeutic potential of HuCNS-SC transplantation, the trial design was impacted by ethical considerations requiring testing in the setting of a fatal disease and enrollment of patients with advanced cognitive disability. In this context, demonstrating safety was the primary objective, as the severe neurological impairment of the patient population was expected to limit measurement of clinical activity.
Methods

Study Design
This research study was conducted as a prospective open-label dose-escalation Phase I trial in patients with advanced INCL and LINCL (clinical trial registration no.: NCT00337636 [ClinicalTrials.gov]). The study protocol was approved by the institutional review board at OHSU, Portland, Oregon, and was carried out at Doernbecher Children's Hospital, OHSU. We confirm that the Declaration of Helsinki protocols were followed and that all families gave written informed consent.
By protocol, eligible patients were 18 months to 12 years of age with mutations in either the CLN1 or CLN2 gene and clinical manifestations consistent with either INCL or LINCL, leukocyte PPT-1 or TPP1 deficiency, cerebral mantle thickness greater than 20 mm, and significant cognitive and developmental dysfunction as measured by the BSID-II and the CAS. A complete list of study inclusion and exclusion criteria can be found in Appendix Table 1 . Fig. 1 . Cross-correction of enzyme deficiency in vivo using HuCNS-SCs. Artist's conceptualization of cell-based crosscorrection as a potential therapeutic strategy. With this experimental approach, PPT-1 and TPP1 are secreted by transplanted HuCNS-SCs and absorbed by host neurons through the mannose 6-phosphate receptor pathway. Cross-correction involves the uptake of these soluble enzymes, resulting in the reduction or stabilization of the accumulating harmful intracellular metabolites. Printed with permission from Andrew J. Rekito.
Treatment
Patients were assigned sequentially in groups of 3 to low-and high-dose HuCNS-SC cohorts. Cell doses were based on allometric scaling (by brain weight) and safety margin from cell doses tested in mice and nonhuman primates. Final human doses reflected an overall safety margin range of 1.4× to 2.9× based on animal toxicology preclinical studies and allometric scaling of cell doses tested in the animal model, which resulted in detection of donor enzyme and positive behavioral outcomes. 26 The targeted total dose was 5 × 10 8 HuCNS-SCs (0.5 × 10 8 cells into each of 6 subcortical sites and 1 × 10 8 cells into each lateral ventricle) for each patient in the low-dose cohort and 1 × 10 9 HuCNS-SCs (1 × 10 8 cells into each of 6 subcortical sites and 2 × 10 8 cells into each lateral ventricle) for each patient in the high-dose cohort.
All surgical procedures were performed by a pediatric neurosurgeon (N.R.S.). Frameless stereotactic navigation was used to target 8 injection sites (4 in each hemisphere), each via a separate 14-mm bur hole to facilitate safe exposure of the atrophic cortical surface: medial frontal, lateral frontal, and central parietal for the subcortical sites, and immediately precoronal for ventricular puncture. This pattern of transplant sites covered a large geographic region of each cerebral hemisphere while avoiding eloquent cortical structures. The multiple injection sites mimicked the transplantation pattern used in a mouse model of INCL in which biological effects were observed. 26 A dual side-port 20-gauge needle was used to deliver the cell suspension to a depth of at least 2 cm below the cortical surface, corresponding to the anatomical location of injections in the animal model that led to migration of donor cells to the cortex. 26 Intracortical injections were not possible in patients with INCL or LINCL due to the presence of severe cortical atrophy. Cells were administered into each lateral ventricle using a ventricular catheter targeted to the Monro foramen.
Due to the allogeneic nature of the transplanted cells, a 12-month course of immunosuppressive therapy was administered to facilitate donor cell engraftment. Tacrolimus was administered orally 3 days prior to transplantation through 28 days posttransplantation to achieve whole blood trough concentrations of 5-10 ng/ml, and thereafter through Month 12 to achieve 2-5 ng/ml. Mycophenolate mofetil was administered posttransplantation for 28 days in 5 of 6 patients. All patients received dexamethasone during the perioperative period and prophylaxis for Pneumocystis pneumonia.
Evaluations
All patients remained near OHSU for the 1st postoperative month to permit frequent evaluations. An independent DMC reviewed the accruing safety data and approved continuance of the trial before each transplant. A minimum of 28 days was required between dosing for each patient.
Subsequent evaluations were performed at 3, 6, 9, and 12 months. A full study procedure schedule is detailed in Appendix Table 2 . Upon completion of the 12-month evaluations, patients were enrolled in a separate 4-year long-term follow-up study. According to the study protocol, separate autopsy consents were obtained for deceased patients during the Phase I and long-term followup studies.
Safety parameters included general physical and neurological assessment (including seizure type and frequency), routine blood and urine analysis, electrocardiography, chest radiography, electroencephalography, and postoperative radiological imaging with brain CT and MRI. Magnetic resonance imaging was conducted posttransplantation within 48 hours, at 6 months, and at 12 months.
A comprehensive effort was undertaken to assess the spectrum of neuropsychological dysfunction manifested by INCL and LINCL. The BSID-II and the CAS were used to assess preliminary clinical activity along with several other instruments to measure cognitive, adaptive, communicative, and developmental function. The Child Health Questionnaire-Parent Report was used to measure quality of life.
Human CNS Stem Cells
HuCNS-SCs are multipotent adult stem cells derived from donated human fetal brain tissue (Methods Appendix). The allogeneic, non-HLA matched HuCNS-SCs for this trial were derived from a single male donor; expressed the neural stem cell markers CD133, nestin, and SOX-2; and lacked expression of mature neuronal markers. 3 The CD133 expression, viability, and sterility of each cell lot were confirmed prior to transplantation. In addition, the cell lots also met a set of other specific release criteria, established with the FDA, relating to identity, potency, and purity.
Molecular Detection of HuCNS-SC Engraftment and Migration
Methods are described in detail in the Methods Appendix. Briefly, genomic DNA was isolated from the HuCNS-SC line used for transplantation and from either formalin-fixed paraffin-embedded or frozen postmortem brain tissue. Engrafted donor cells were detected using standard and quantitative PCR methods. Chromosome Y-nested PCR was used to detect donor cells in the postmortem female brain. For postmortem male brain specimens, HLA typing identified alleles at the HLA-DRB1 locus mismatched with HuCNS-SCs, and nested PCR was used to achieve high sensitivity and specificity for donor cells to quantify the percentage of donor cell engraftment relative to host cell numbers. Postmortem measurement of brain PPT-1 or TPP1 produced by HuCNS-SC transplantation was generally not feasible because the enzyme assay lacks the sensitivity to reliably detect increases due to donor-derived protein from the background activity present in the host.
Results
Study Population
Six patients (4 males and 2 females) were enrolled in the study. Patient characteristics and treatments are shown in Table 1 . Two patients had INCL and 4 patients had LINCL. A spectrum of abnormalities was observed across the 6 patients. BSID-II and CAS assessments revealed significant neuropsychological impairment reflective of advanced disease in all patients at study entry. Consistent with disease severity, significant cognitive dysfunction, reduced motor strength, absence of independent ambulation, and seizures were the most prominent clinical features at enrollment. Severe cerebral atrophy, ex vacuo enlargement of the ventricular system, and marked neurological and neuropsychological impairment were noted in 4 patients (Cases 1, 2, 4, and 5); 2 patients (Cases 3 and 6) had less cerebral atrophy and higher levels of function. The latter 2 patients also had no apparent history of seizures; the other 4 had diagnoses of multiple seizure types of varying frequency. The most common EEG characteristics at study entry were generalized slowing and disorganization, consistent with NCL.
Safety Profile
Most adverse events occurred within 30 days of transplantation, were mild to moderate intensity, and were consistent with adverse events expected with immunosuppressive agent therapy (tacrolimus and MMF) or progressive NCL. All patients experienced anemia, vomiting, and hypomagnesemia, and 4 experienced seizures, fever, diarrhea, abdominal discomfort, and upper respiratory tract infection. Five patients had 1 or more severe adverse events, which included 2 with eye disorders (1 with blindness that is typical of the underlying NCL) and 2 with anemia; 4 had moderate hypomagnesemia or gastrointestinal disorders (3 with vomiting and 2 each with nausea or abdominal discomfort). The incidence of adverse events did not increase in the high-dose cohort, and adverse events were generally transient and manageable with standard supportive care. Hypomagnesemia resolved with tacrolimus dosing adjustment.
No leukopenia or opportunistic infections were reported. All patients maintained normal kidney function and lipid profiles during the 12-month study period. Four patients experienced 16 serious adverse events that initiated or prolonged hospitalization at 2-366 days posttransplantation ( Table 2 ). The incidence of serious adverse events was unrelated to dose. Three serious adverse events occurred within the first 30 days posttransplantation, 4 occurred within 30-90 days, and 9 occurred 135-366 days posttransplantation. Reduced oral intake and dysphagia resulted in gastrostomy placement in 3 patients; all other serious adverse events in this Phase I study resolved without sequelae except for one that resulted in death.
Three patients (Cases 3, 4, and 6) were alive at 1559, 1461, and 1293 days posttransplantation, respectively, at the time of data cutoff. One patient (Case 2) died at 357 days posttransplantation of sequelae related to seizures and underlying NCL. Blood cultures, brain CT scanning, and CSF obtained during the preterminal hospitalization showed no evidence of an infectious or acute CNS process. Brain autopsy revealed severe generalized atrophy and histological features of NCL including diffuse intraneuronal deposits. The expected artifact created by the needle tracks from the transplant procedure was identified; no clusters of immune cells, neoplasia, or host cell atypia were evident (Appendix Fig. 1 ). No adverse effects of transplanted HuCNS-SCs were apparent. Details of the patient's admission to the hospital, subsequent death, and autopsy results were immediately reviewed by the DMC and were reported to the FDA in accordance with safety reporting guidelines, and were adjudicated as unrelated to the surgical, immunosuppressive, cell transplantation, or other protocols of the study. During long-term follow-up, 2 patients (Cases 5 and 1) also died of causes related to NCL at 918 days and 1245 days posttransplant, respectively. Postmortem examination findings were similar to those in Case 2, with no evidence of unexpected cellular atypia or focal collection of inflammatory cells associated with the transplant sites in either patient. Pathological changes typical of LINCL were noted, including severe cerebral atrophy, neuronal storage material, and neuronal loss, as well as expected diffuse gliosis and activated microglia. The circumstances of the deaths for these 2 patients (Cases 5 and 1), and the subsequent brain autopsy results, were also reviewed by the DMC and were provided to the FDA.
Neurological, Neuropsychological, and Radiological Outcomes
Neurological changes observed during the follow-up examinations were consistent with the expected natural course of disease progression for each patient. No precipitous or focal changes in neurological function were noted posttransplantation. In 4 patients with pretransplantation seizures, no clinically meaningful pattern of change in seizure type or frequency was observed. One patient had onset of infrequent atonic seizures 6 months after transplantation, with characteristic NCL-related findings on EEG, without focality. The other patient with no history of seizures at the time of enrollment remained free of seizures during the study period. The most common EEG characteristic at study entry and during follow-up was generalized slowing and disorganization, consistent with NCL. No focal epileptiform activity suggestive of any acute or delayed response to the transplant procedure was observed in any patient.
The pattern of results seen with the BSID-II and the CAS represented the general trend observed in the other neuropsychological tests administered at baseline and follow-up. The outcomes of all neuropsychological tests were consistent with the refractory nature of disease at enrollment and progressive global CNS dysfunction secondary to NCL. Significant disparity was noted between the patients' chronological age and overall functional mental age. In addition, patients with the lowest neuropsychological scores also tended to have the most pronounced cerebral atrophy at baseline and at study end. Improvement in neuropsychological test results following transplantation was neither expected nor observed in these cases of advanced NCL (Appendix Fig. 2) . Quality of life outcomes measured by the Child Health Questionnaire-Parent Report were either stable or tended to show slight improvement from baseline to the final posttransplantation assessment across all patients.
Diffuse cerebral atrophy reflective of neuronal loss and ex vacuo enlargement of the ventricular system were the most common radiological findings at baseline. Variability was expected and observed among the 6 patients at study entry; 4 patients (Cases 1, 2, 4, and 5) had severe atrophy and 2 patients (Cases 3 and 6) had mild atrophy (Fig. 2) .
HuCNS-SC Engraftment and Migration
Analysis of donor cell engraftment in the postmortem brain was conducted for the 3 patients who died. At the time of autopsy in Case 5, the right hemisphere was sectioned into 5 equal axial slices (approximately 1 cm thick). The second slice from the upper hemisphere (supraventricular region most proximal to the site of transplantation) and fourth slice (level of the basal ganglia and genu of the internal capsule well inferior to the transplantation sites) were frozen for PCR-based detection of HuCNS-SCs (Fig. 3A) . were collected from Slice 4. Samples AF1 and P included faint needle track remnants corresponding to the needle track artifact seen on the immediate posttransplantation MR image and to the stereotactic targeting. Samples with no associated needle tracks, and distant from the stereotactic targets (AF2, PF, DF, BG, and DP), were collected to assess for HuCNS-SC migration. The remaining 3 brain slices from the right hemisphere and the entire left hemisphere were fixed in formalin to preserve tissue for pathological and safety analysis.
HuCNS-SCs were detected using nested PCR with 2 HLA-DRB1 allele locus mismatched sequences (Methods Appendix). Samples AF1, AF2, P, DF, and BG were positive for both alleles (Fig. 3B) . HuCNS-SCs detected in Samples AF2, DF, and BG indicate migration of the donor cells remote from the site of initial transplantation. In Samples DF and BG (genu of the internal capsule), migration was at least 3 cm distant to the closest needle track remnant.
The percentage of HuCNS-SCs was determined in Samples AF1, AF2, P, DF, and BG using HLA-DRB1*01 quantitative duplex PCR. Figure 3C also shows extrapolation of the quantitative PCR percentage to relative donor/ host cell ratio per location. The highest percentages of HuCNS-SCs were detected in samples associated with needle tracks: 0.067% in Sample AF1 and 0.13% in Sample P. In samples not associated with needle tracks, the percentage of HuCNS-SCs migrating inferiorly from the frontal lobe injection site was considerably higher (0.04% in Sample DF) than the percentage of cells migrating lat- erally (< 0.001% to > 0.0001% in Sample AF2) or most inferiorly (< 0.001% to > 0.0001% in Sample BG). These results suggest either a preferential directional migration pattern of HuCNS-SCs toward the basal ganglia and deeper white matter tracts, or regional variability in HuCNS-SC survival and migration. Phenotypic analysis of individual donor cells based on HLA PCR was not technically possible because tissue samples were homogenized for the quantitative duplex PCR analysis.
As the patient in Case 2 was the first to die and to avoid excluding any part of the brain from pathological examination for safety concerns, the entire brain was subjected to formalin fixation for 1 month for histological and microscopic analysis. Given that postmortem frozen tissue was not available, a highly sensitive donor-specific chromosome Y-nested PCR assay was developed to detect HuCNS-SCs (Methods Appendix) as the genomic DNA isolated from paraffin-embedded tissue was highly degraded due to the extended formalin fixation. Y-fluorescence in situ hybridization was also attempted in this specimen, but the high degree of background autofluorescence from the NCL deposits prohibited analysis and thus also any potential donor cell phenotype analysis. Using this PCR assay, chromosome Y was detected in 5 of 7 samples with identified needle tracks from the left hemisphere, and in 9 of 12 samples from the right hemisphere (Appendix Fig. 3 ). One sample (4A2) below the level of the needle track was also positive by the Y-nested PCR assay for HuCNS-SCs, consistent with detection of donor cell migration in at least 1 transplantation site. Quantitative PCR was attempted in this specimen but led to irreproducible results, because of the paraffin-embedded tissue, highly degraded DNA, and inhibition of polymerase enzyme activity secondary to formalin fixation.
For the patient in Case 1, the first to undergo transplantation with HuCNS-SCs, the brain specimen was prepared in a similar manner as that for the patient in Case 5. Tissue samples from the estimated areas of donor cell transplantation were collected from 2 frozen axial sections from the right hemisphere and assayed for HuCNS-SCs by nested PCR for the HLA DRB1*01 allele (Appendix Fig. 4) . No engraftment was detected in these tissue samples. The lack of detection of HuCNS-SCs by PCR methodology does not exclude the possibility that the cells engrafted in other regions of the brain that were not tested. It is also important to note that failure to detect the presence of donor cells, regardless of etiology, was not associated with evidence of an autoimmune reaction, cerebritis, or focal areas of increased astrogliosis/microglial activation.
Discussion
Completion of this trial represents the first instance of direct transplantation of allogeneic neural stem cells into the human brain, and thus may have relevance to a wide range of human CNS disorders that remain impenetrable to small molecules and other biological therapeutic approaches. 1, 10, 13, 14, 24, 27, 31 Using CNS transplantation of a purified population of neural stem cells, the study objectives of demonstrating feasibility, safety, and tolerability were met. The study was conducted in a purely pediatric population with a rationale focused on cell-based crosscorrection in a lysosomal storage disorder, an approach that could overlap with other neurodegenerative disorders.
Previous trials of CNS cellular therapy have been conducted in Parkinson disease 4, 12, 17 and Huntington disease 8 using postmitotic mixed neuronal cell populations derived from fetal mesencephalic tissue. 4, 8, 12, 15, 17, 18 In contrast, purified HuCNS-SCs are derived from a single donor, are expandable, bankable, and have inherent biological properties of self-renewal and multilineage differentiation, making their use potentially applicable to a wide variety of CNS disorders.
No complications were directly attributed to the transplanted HuCNS-SCs in this trial, and no unexpected changes were observed in neurological function or MRI results. The pattern of adverse events and overall safety profile observed during the 1st year posttransplantation were consistent with the effects of immunosuppressive therapy and the expected disease course. Indeed, the eligibility criteria for this first-in-human test of neural stem cell transplantation was restricted to patients who were in the advanced stage of a serious, progressive, and uniformly fatal neurodegenerative disorder. As such, the pattern and frequency of adverse events observed during the study were expected based on the natural history of the disease, and the independent DMC overseeing the trial found no individual adverse event or pattern that could be related to the HuCNS-SC transplantation or to the related study immunosuppressive and surgical transplantation protocols. Because of the novel nature of this trial and its implementation in the pediatric age group, the trial physicians and sponsor maintained particularly close communication with the FDA, which exceeded standard reporting guidelines.
Evidence of donor cell engraftment in 2 of 3 postmortem brains at 357 and 918 days posttransplantation demonstrates the immune privilege of the CNS and durable persistence of HuCNS-SCs with transient posttransplantation immunosuppression. Evidence of cell migration remote from the site of initial transplantation and the presence of measurable levels of donor cells by quantitative PCR in this early study recapitulate the results of preclinical in vivo investigations 26 and support the potential for a durable effect in humans based on a single intervention. The observation that a higher proportion of transplanted cells appear to have migrated ventrally rather than anteriorly from their injection sites may indicate that transplanted cells use host structures, such as fiber tracts or blood vessels, as preferred pathways for migration.
Further characterization of donor cell phenotype and the total number of surviving cells in host tissue is an important but technically challenging goal, due to the extended postmortem intervals and very large hemispheric volumes inherent in human pathological anatomy. Future development of validated techniques to assess the anatomical outcomes of transplantation in these patients may include identification of transplanted cells by in situ hybridization, quantitative evaluation of host cell enzyme levels, and/or quantitative assessment of pathological substrate accumulation.
The failure to confirm HuCNS-SCs in 1 patient at 1245 days posttransplantation could be attributed to multiple factors, including cell dose, single versus dual agent immunosuppression, or the effect of host-activated microglia known to be associated with advanced disease. However, the lack of persistent HuCNS-SC genomic DNA provides a valuable negative control, indicating that nonviable cells do not result in false-positive donor cell detection and that, more importantly, the loss of donor cells, regardless of mechanism, does not result in an obvious host inflammatory reaction or safety concern.
Detection of clinical activity in an open-label study focused on patients with advanced and progressive neurodegenerative disease is a well-known challenge. The results of this Phase I study cannot confirm whether the natural history of the disease was altered by HuCNS-SC transplantation. Subsequent investigations should ideally target earlier disease stages to maximize the benefit of neuroprotection by donor cells and to enhance the ability to demonstrate clinically meaningful outcomes. Given the low prevalence of the disease, the conduct of pivotal trials in NCL will greatly benefit from development of innovative study designs and validated surrogates of disease progression.
Conclusions
This Phase I study represents the first-in-human investigation of purified neural stem cell transplantation.
Despite the underlying medical fragility of this patient population, which suffers from the late-stage effects of a fatal neurodegenerative disorder, an intensive clinical, serological and radiological surveillance protocol with real-time FDA disclosure revealed no apparent transplantation-related serious adverse events. The discovery of transplanted cells in postmortem host brain years after implantation and long after the cessation of immunosuppression suggests that this approach may have significant therapeutic potential for the treatment of human disease. Further studies of neural stem cell transplantation for the treatment of NCL and potentially for a wide range of other neurodegenerative disorders may be indicated.
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Methods Appendix
Preparation of Human CNS Stem Cells (HuCNS-SCs) for Transplantation
To produce HuCNS-SCs, a subset of dissociated brain cells was isolated using fluorescence-activated cell sorting on the basis of high plasma membrane expression of CD133 and low to negative expression of CD24. The HuCNS-SCs were further purified by selective passage-expansion as neurospheres in defined serum-free medium. a This process was used to create a master cell bank from a single male donor, from which multiple working cell banks were derived. Final cell lots for transplantation into patients for this trial were then derived from working cell banks. The HuCNS-SC transplant was provided as a single-use injectable suspension.
Isolation of Genomic DNA From the HuCNS-SC Line, From Frozen Brain Tissue (Cases 1 and 5), and From
Paraffin-Embedded Brain Tissue Sections (Case 2)
For isolation of genomic DNA from the HuCNS-SC line, approximately 25 × 10 6 HuCNS-SCs were placed in a 1.5-ml microcentrifuge tube and washed twice with 1 ml phosphate-buffered saline (PBS), and then 400 μl of proteinase K buffer (0.05 M Tris pH 8.0, 0.1 M NaCl, 0.5% sodium dodecyl sulfate, and 2 mM EDTA) was added, followed by 5 μl of proteinase K (20 mg/ml stock, Roche Applied Science), and was mixed. The mixture was incubated at 55°C for 20 hours, and then 75 ml of 8 M potassium acetate was added and mixed thoroughly. One milliliter of phenol chloroform isoamyl alcohol (50:48:2, Invitrogen) was added, mixed, and centrifuged at 10,000g for 20 minutes at room temperature. The top aqueous layer was removed with a cut-off-tip 1-ml pipette tip and was transferred to a new 1.5-ml microcentrifuge tube. Two volumes (1 ml) of ethanol (room temperature) was added, mixed, and centrifuged at 10,000g for 30 minutes to pellet the genomic DNA. The supernatant was removed, and the DNA pellet was resuspended in 50 ml of TE containing 1 mg of RNase A (DNase-free), mixed, and incubated at 37°C for 1 hour. Genomic DNA concentration was determined by OD 260 .
For isolation of genomic DNA from frozen brain tissue (Cases 1 and 5), 1-to 3-g samples were cut with a scalpel from partially thawed brain slices, weighed, and rinsed 4 times with PBS. Tissue samples were minced with a scalpel, and 400 ml of proteinase K buffer was added for each 0.1 g of tissue. The genomic DNA purification procedure described for the HuCNS-SC line was scaled up as appropriate.
For isolation of genomic DNA from paraffin-embedded brain tissue sections (Case 2), 10 paraffin sections (10 mm each) from each tissue block were placed into a single 1.5-ml microcentrifuge tube. Paraffin was removed by adding 1 ml of Histo-Clear (Electron Microscopy Sciences) followed by incubation at room temperature for 5 minutes with rocking. The tube was centrifuged at 6000g for 2 minutes at room temperature and the supernatant removed with a 1-ml pipette tip. The Histo-Clear wash was repeated twice. The tissue pellet was washed with 1 ml of ethanol for 5 minutes with rocking at room temperature. The tube was centrifuged at 10,000g for 2 minutes at room temperature and the supernatant removed with a 1-ml pipette tip. The ethanol wash was repeated once. The open tube containing the tissue pellet was placed in a 56°C heat block to dry for 80 minutes. After the tissue pellet was dry, 400 μl of proteinase K buffer was added and genomic DNA was isolated as described for the HuCNS-SC line, except the genomic DNA pellet was resuspended in a final volume of 32 ml of TE.
Standard, Nested, and Quantitative Polymerase Chain Reaction (PCR)
Standard PCRs were conducted using the DNA Engine Dyad Peltier thermal cycler (Bio-Rad Laboratories). Primary PCRs were performed using the Expand High Fidelity PCR System (Roche Applied Science) under the following conditions: 5-minute incubation at 95°C to denature the genomic DNA followed by 40 cycles at 94°C for 30 seconds, 60°C for 1 minute for chromosomes Y and X (55°C for 2 minutes for HLA-DRB1*01 and HLA-DRB1*04), and 72°C for 15 seconds. Polymerase chain reactions were carried out in a 25-ml volume containing 200 μM of each deoxyribonucleotide triphosphate (dNTP), 300 nM of each primer, 3.3 U of Expand High Fidelity enzyme mix for chromosomes Y and X (6.6 U for HLA-DRB1*01 and HLA-DRB1*04), 1.5 mM MgCl 2 , and 1 μg of genomic DNA for chromosomes Y and X (2 μg for HLA-DRB1*01 and HLA-DRB1*04) or 2 ml of genomic DNA isolated from paraffin sections. Genomic DNA isolated from paraffin sections was heated for 1 hour at 95°C to reverse the cross-linking prior to the PCR. Oligonucleotide sequences of primers used in the primary PCRs were as follows:
Chromosome Y forward primer 5ʹAGTGTTTGAGTCCCAGCCCT3ʹ Chromosome Y reverse primer 5ʹTCTTCGCCGTTCTGAGGCAT3ʹ Chromosome X forward primer 5ʹCTCATTCCCAGGATGCCTCC3ʹ
Appendix Fig. 1 . Case 2. Low (upper) and high (lower) magnification of a typical surgical artifact from needle insertion and cell suspension injection at 11 months posttransplantation of human CNS stem cells (HuCNS-SCs). Visible changes related to insertion of the needle for cell deposition were minimal. Gliotic changes in the area immediately adjacent to the residual needle track were negligible as shown in the higher magnification. No inflammatory cells collected to suggest any localized immune reaction to the cell transplant. Similarly, no infarction, hemorrhage, cyst formation, neoplasm, or abnormal host cell reaction was evident. The findings of generalized reactive astrocytes, microglia, and enlarged neurons typical of infantile neuronal ceroid lipofuscinosis (INCL) were noted and were considered consistent with the patient's diagnosis and disease course. H & E.
Chromosome X reverse primer 5ʹGAGATGACCAGGGGAACCCA3ʹ HLA-DRB1*01 forward primer 5ʹTTCTCAGGAGGCTGCCCGT3ʹ HLA-DRB1*01 reverse primer 5'TGCATCTTTCCAGCAACCGC3ʹ HLA-DRB*04 forward primer 5ʹTTCCCCGGAGGCCGCTTCT3ʹ HLA-DRB1*04 reverse primer 5ʹAGTATCTGTCCAGGAACCGC3ʹ
Nested PCRs were performed as follows: 2-minute incubation at 95°C to denature the template followed by 20 cycles at 94°C for 20 seconds, 60°C for 1 minute, and 72°C for 15 seconds. Polymerase chain reactions were followed by single sequential incubations at 72°C for 2 minutes, 60°C for 20 minutes, 50°C for 20 minutes, 40°C for 20 minutes, and finally 10°C hold. Polymerase chain reactions were carried out in a 25-ml mixture volume with 200 mM of each dNTP, 300 nM of each primer, 1 ml (3.3 U) of Expand High Fidelity enzyme mix, 1.5 mM MgCl 2 , and 0.1-1 ml of the primary PCR products as templates. Oligonucleotide sequences of the primers used in the nested PCRs were as follows:
Chromosome Y forward primer 5ʹCCAGCCACCTTTGAGTTGTG3ʹ Chromosome Y reverse primer 5ʹGGACGAGGACCGTGACCTA3ʹ Chromosome X forward primer 5ʹTGGTTCCACAGCTCTCTCCG3ʹ Chromosome X reverse primer 5ʹCGCCCCTACCTGCCCTTTTT3ʹ HLA-DRB1*01 forward primer 5ʹGACCGGATCCTTCGTGTCC3ʹ HLA-DRB1*01 reverse primer 5ʹCATTCAAACTTAAGCTGCCACAAG3ʹ HLA-DRB*04 forward primer 5ʹAACCGGATCGTTCTTGTCCC3ʹ
HLA-DRB1*04 reverse primer 5ʹGACACTCATGTTTAACCTGCTCCAA3ʹ
Quantitative PCRs were carried out using a Chromo4 thermal cycler (Bio-Rad Laboratories). The Expand High Fidelity PCR system was utilized for standard primary PCRs for both chromosome X and HLA-DRB1*01 as described above, except 20 cycles were performed to remain within the linear range of the PCR. Nested quantitative PCR was performed using iQ SYBR Green Supermix (Bio-Rad Laboratories). Thirty cycles were performed using the identical cycling conditions described above for nested PCR; 300 nM of each primer was used per reaction and either 0.1 ml for HLA-DRB1*01 or 0.5 ml for chromosome X of the primary PCR products were used as templates. The percentage of engrafted donor cells was estimated by calculation from a standard curve in which increasing donor cell number genomic DNA was spiked to a constant amount of HLA-DRB1 nonmatching genomic DNA in excess derived from HuCNS-SCs of different donor background.
Agarose Gel Electrophoresis
Agarose gel electrophoresis was performed using the Wide Mini-Sub Cell GT system (Bio-Rad Laboratories). Polymerase chain reaction products (10 ml) were loaded into each well for analysis. One mg of 100-bp DNA ladder molecular weight standards (Invitrogen) was loaded per lane. Agarose gels (2%) were cast and electrophoresis was carried out in Tris-borate-EDTA buffer: 40 mM Tris pH 8.0, 40 mM boric acid, and 1 mM EDTA. Gels were imaged with FluorChem SP imager (Alpha Innotech Corp.).
